Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On Tuesday, Moderna Inc. ( MRNA , Financial) CEO Stéphane Bancel made a bold prediction at the company's first in-person Science and Technology Day since 2019, saying mRNA technology has the unique opportunity “to change medicine forever.”

Moderna CEO: Our Technology Has the Opportunity to Change Medicine

Advanced Micro Devices

Off and on the price chart these three blue-chip tech stocks look great to buy following earnings beats and attractive price charts. The post 3 Blue-Chip Tech Stocks to Buy Now appeared first on InvestorPlace.

3 Blue-Chip Tech Stocks to Buy Now

CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Present at the UBS 2022 Global Healthcare Conference

Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.

Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?

But it's not the stock that investors should be worried about.

Moderna Just Made a $700,000 Mistake

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant screenings are soon to start for a Phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research (CFHR) in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa. The IAVI-sponsored trial, IAVI G003, builds on progress in HIV vaccine research.

IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program

Moderna, Inc. (NASDAQ:MRNA ) Annual Science and Technology Day Conference May 17, 2022 9:00 AM ET Company Participants Stéphane Bancel - CEO Melissa Moore - Chief Scientific Officer, Scientific Affairs Jean Sung - Senior Director, Respiratory Delivery Phil White - Vice President, CMC Lifecycle Management Conference Call Participants Stéphane Bancel Well, good morning, everybody. Good afternoon, if you're alive.

Moderna, Inc. (MRNA) Annual Science and Technology Day Conference (Transcript)

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery Moderna's 5th Annual Science and Technology Day presentations highlight continued focus, safety and innovation of our intramuscular lipid nanoparticles (LNPs) delivery system in vaccines CAMBRIDGE, MA / ACCESSWIRE / May 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new research findings as part of the Company's fifth annual Science and Technology Day. Moderna continues to highlight investments in the expansion of the utility of the mRNA platform, characterization of the Company's vaccines, biodistribution of vaccines, and using clinical data to predict vaccine dosing.

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

Moderna Inc. (NASDAQ:MRNA) has been strong since it rolled out COVID-19 vaccines. The demand for vaccines has started to slow down.

What next as Moderna finds support at $130?

CRISPR Therapeutics

These two companies have been southbound lately.

2 Stocks With 75% to 183% Upside, According to Wall Street

After a strong first quarter, fresh risks and potential new rewards are both coming into view.

2 Problems and (Maybe) 1 Opportunity for Moderna This Summer

MRNA stock has been rising for some time now. However, it may see a short-term decline due to the recent departure of its CFO.

Moderna Stock Will Come Back Stronger After CFO Exit

AstraZeneca

Inovio Pharmaceuticals

Johnson & Johnson

Pfizer

Is This Vaccine Stock in Trouble -- or Ready for a Rebound?

The new Moderna Therapeutics Inc (NASDAQ:MRNA) chief financial officer has left the company one day after assuming the post.  Jorge Gomez is departing after questions were raised about his tenure at his former employer, Dentsply Sirona, a dental-supply company, state media reports.

Moderna CFO Jorge Gomez exits after just one day in the role

Novavax

A slew of regulatory catalysts could bring delight -- or disaster.

Here's Why June Could Make Or Break These 3 Vaccine Stocks

Jorge Gomez started as Moderna's CFO on Monday. His departure was announced on Wednesday, following an SEC filing by his ex-employer Dentsply Sirona.

A Moderna exec will be paid $700,000 despite leaving his job after 1 day, report says

Why Moderna Stock Swooned Today

The vaccine had an estimated efficacy of 88% at least 14 days after the first dose, researchers found.

Moderna Covid Vaccine Safe And Effective In Kids Ages 6-11, Study Finds

Moderna Inc (NASDAQ: MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately.  The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ: XRAY), of an.

Why Did Moderna CFO Exit Just A Day After Taking Charge

Wednesday's announcement comes after Gomez's former employer, Dentsply Sirona Inc., disclosed an ongoing internal investigation related to financial reporting.

Moderna's new CFO abruptly resigns after 2 days

Moderna's new financial chief left the COVID-19 vaccine maker after just one day on the job as his old employer revealed it had launched an internal probe of its bookkeeping. Moderna Chief Financial Officer Jorge Gomez's abrupt tenure at the company ended Tuesday — within a day of dental equipment maker Dentsply Sirona's disclosure of.

Moderna CFO Jorge Gomez exits after one day as old company launches probe

Moderna Inc. surprised investors Wednesday with the news that its chief financial officer has departed the company just two days after taking up the position, following the disclosure of an internal probe into financial reporting at his former employer.

Moderna CFO out after two days in the role as former employer Dentsply discloses probe of financial reporting

Moderna Inc said on Wednesday its newly appointed chief financial officer, Jorge Gomez, departed from the drugmaker after his former employer Dentsply Sirona Inc disclosed an internal probe into financial reporting.

Moderna new CFO leaves as former employer launches probe

Moderna Inc. MRNA, -2.56% said Wednesday its recently appointed chief financial officer, Jorge Gomez, has departed the company with immediate effect. The company said the move comes after the May 10 disclosure from Dentsply Sirona Inc. XRAY, -7.31% of an internal investigation into certain matters, including financial reporting.

Moderna's recently appointed CFO is out after former employer Dentsply discloses internal probe of financial reporting

CAMBRIDGE, MA / ACCESSWIRE / May 11, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the Company, effective immediately. The announcement follows the May 10 public disclosure by Mr.

News for Moderna Stock (MRNA)